Maraviroc in treatment-experienced patients with HIV-1 infection – experiences in routine clinical practice

S. Reuter, P. Braken, B. Jensen, S. Sierra-Aragon, M. Oette, M. Balduin, R. Kaiser & D. Häussinger
Objectives: Maraviroc (MVC) has become a valuable HIV treatment option, but few data are available about the efficacy of MVC in routine clinical use to date. It has to be determined when and how to use MVC beyond deep salvage situations. Methods: In this prospective single-center observational study[for full text, please go to the a.m. URL]